Quarterly update on resumption progress and continued suspension of trading
Filed with HKEX · Stock code 2627 · · 4 pages · English
Summary by 6ix AI
Ab&B Bio-Tech Co., Ltd. JS has issued a quarterly update regarding its progress on resumption and the continued suspension of trading of its shares. The company is currently undergoing an independent forensic investigation and an internal control review as part of the resumption guidance set by the Stock Exchange. The publication of the company's outstanding financial results has been delayed due to the resignation of its previous auditor and the ongoing audit process. Trading in the company's shares has been suspended since early April and will remain so until further notice, with updates to be provided as necessary.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Ab&B Bio-Tech Co., Ltd. JS on 6ix
Earlier from Ab&B Bio-Tech Co., Ltd. JS
- List of directors and their roles and functions
- (I) resignation of executive director and chief financial officer (ii) nomination of executive directors (iii) appointment of chief financial officer (iv) change of members of board committees (v) appointment of board secretary and joint company secretary (vi) waiver from strict compliance with rules 3.28 and 8.17 of the listing rules (vii) change of authorized representative and (viii) continued suspension of trading
- Voluntary announcement - IND approval by china CDE for mRNA mpox vaccine
Later from Ab&B Bio-Tech Co., Ltd. JS
- Monthly return of equity issuer on movements in securities for the month ended 30 September 2026
- Resignation of non-executive director; and (2) continued suspension of trading
- Monthly return of equity issuer on movements in securities for the month ended 31 October 2026
Follow Ab&B Bio-Tech Co., Ltd. JS into a list and get an email when it puts out news.
Follow Ab&B Bio-Tech Co., Ltd. JS